Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.

Ghadjar, Pirus; Hayoz, Stefanie; Bernhard, Jürg; Zwahlen, Daniel R; Hölscher, Tobias; Gut, Philipp; Polat, Bülent; Hildebrandt, Guido; Müller, Arndt-Christian; Plasswilm, Ludwig; Papachristofilou, Alexandros; Schär, Corinne; Sumila, Marcin; Zaugg, Kathrin; Guckenberger, Matthias; Ost, Piet; Reuter, Christiane; Bosetti, Davide G; Khanfir, Kaouthar; Gomez, Silvia; ... (2021). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. European urology, 80(3), pp. 306-315. Elsevier 10.1016/j.eururo.2021.05.033

[img] Text
1-s2.0-S0302283821018029-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

BACKGROUND

Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP).

OBJECTIVE

To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT.

DESIGN, SETTING, AND PARTICIPANTS

SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP.

INTERVENTION

Patients were randomly assigned to conventional-dose (64 Gy) or dose-intensified SRT (70 Gy) to the prostate bed without hormonal therapy.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), acute and late toxicity (Common Terminology Criteria for Adverse Events v4.0), and quality of life (QoL).

RESULTS AND LIMITATIONS

Between February 2011 and April 2014, 350 patients were randomly assigned to 64 Gy (n = 175) or 70 Gy (n = 175). Median prostate-specific antigen at randomization was 0.3 ng/ml. After median follow-up of 6.2 yr, the median FFBP was 8.2 yr in the 64 Gy arm and 7.6 in the 70 Gy arm (log-rank p = 0.4), with a hazard ratio of 1.14 (95% confidence interval 0.82-1.60). The 6-year FFBP rates were 62% and 61%, respectively. No significant differences in clinical PFS, time to hormonal treatment, or OS were observed. Late grade 2 and 3 genitourinary toxicity was observed in 35 (21%) and 13 (7.9%) patients in the 64 Gy arm, and 46 (26%) and seven (4%) in the 70 Gy arm, respectively (p = 0.8). Late grade 2 and 3 gastrointestinal toxicity was observed in 12 (7.3%) and seven patients (4.2%) in the 64 Gy arm, and 35 (20%) and four (2.3%) in the 70 Gy arm, respectively (p = 0.009). There were no significant differences in QoL.

CONCLUSIONS

Conventional-dose SRT to the prostate bed is sufficient in patients with early biochemical progression of prostate cancer after RP.

PATIENT SUMMARY

The optimal radiation therapy dose for patients who have increased tumor markers after surgery for prostate cancer is unclear. We found that administering a higher dose only increased the gastrointestinal side effects without providing any benefits to the patient. This clinical trial is registered on ClinicalTrials.gov as NCT01272050.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Ghadjar, Pirus; Bernhard, Jürg; Plasswilm, Ludwig; Zaugg, Kathrin; Thalmann, George and Aebersold, Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0302-2838

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

01 Jul 2021 10:36

Last Modified:

18 Aug 2021 01:34

Publisher DOI:

10.1016/j.eururo.2021.05.033

PubMed ID:

34140144

Uncontrolled Keywords:

Biochemical progression Prostate cancer Salvage radiotherapy

BORIS DOI:

10.48350/157222

URI:

https://boris.unibe.ch/id/eprint/157222

Actions (login required)

Edit item Edit item
Provide Feedback